Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm

Cardiovascular Drugs and Therapy

Volumn 24, Issue 5-6, 2010, Pages 373-378

  Golledge, Jonathan ^a   Cullen, Bradford ^a   Moran, Corey ^a   Rush, Catherine ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Aneurysm; Aorta; Atherosclerosis; Mouse model; Simvastatin

Indexed keywords

APOLIPOPROTEIN E; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ECHOCARDIOGRAPHY; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; MACROPHAGE MIGRATION; MALE; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; LIPIDS; MALE; MICE; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LIPOPROTEIN; SIMVASTATIN;

EID: 79958240216     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6262-8     Document Type: Article

References (28)

1. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-13.
2. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg. 2002;35:72-9.
3. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol. 1999;18:52-7. (Pubitemid 29253669)
4. Wilmink AB, Hubbard CS, Day NE, Quick CR. Effect of propanolol on the expansion of abdominal aortic aneurysms: a randomised study. Br J Surg. 2000;87:499.
5. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606-10. (Pubitemid 33664907)
6. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001;88:1066-72. (Pubitemid 32868660)
7. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle- Chavez SJ, Mao D, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92-101. (Pubitemid 40040997)
8. Zhang Y, Naggar JC,Welzig CM, Beasley D,Moulton KS, Park HJ, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol. 2009;29:1764-71.
9. Kajimoto K, Miyauchi K, Kasai T, Shimada K, Kojima Y, Shimada A, et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009;206:505-11.
10. Nakamura K, Sasaki T, Cheng XW, Iguchi A, Sato K, Kuzuya M. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009;206:355-61.
11. Chen Z, Fukutomi T, Zago AC, Ehlers R, Detmers PA, Wright SD, et al. Simvastatin reduces neointimal thickening in lowdensity lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 2002;106:20-3. (Pubitemid 34747436)
12. Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. Immunol 2006;177:3028-34. (Pubitemid 44277819)
13. Bisgaier CL, Essenburg AD, Auerbach BJ, Pape ME, Sekerke CS, Gee A, et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res. 1997;38:2502-15. (Pubitemid 28028135)
14. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361-9.
15. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-8. (Pubitemid 36337226)
16. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and pro6teolysis. Circulation 2005;111:2219-26. (Pubitemid 40632438)
17. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c- Jun N-terminal kinase. Nat Med. 2005;11:1330-8. (Pubitemid 41752914)
18. King VL, Trivedi D, Gitlin JM, Loftin CD. Selective cyclooxygenase- 2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol. 2006;26:1137-43. (Pubitemid 43732124)
19. Martin-McNulty B, Tham DM, da Cunha V, Ho JJ, Wilson DW, Rutledge JC, et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1627-32. (Pubitemid 37108208)
20. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J. Whole genome expression analysis within the angiotensin IIapolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics. 2009;10:298.
21. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, et al. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 2010;210:88-93.
22. Moran CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res. 2009;46:209-17.
23. Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:380-6. (Pubitemid 46143055)
24. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003;167:187-94. (Pubitemid 36773519)
25. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrün M, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21-6. (Pubitemid 43842752)
26. Mosorin M, Niemelä E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg. 2008;7:578-81.
27. Ferguson C, Clancy P, Bourke B, Walker P, Dear A, Buckenham T, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159:307-13.
28. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromsø Study, 1994-2001. Circulation 2009;119:2202-8.